Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of ophthalmic faricimab with other anti-vascular endothelial growth factor (VEGF) and/or other therapies (e.g., photodynamic therapy) for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema (DMO), and/or visual impairment due to macular edema secondary to retinal vein occlusion (RVO) in the same eye has not been evaluated.

MANAGEMENT: According to some authorities, concomitant use of ophthalmic faricimab with other anti-VEGF products, systemic or ocular, and/or other therapies (e.g., photodynamic therapies) in the same eye should generally be avoided. Clinical data characterizing the extent of this interaction are not available. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

The recommended maximum number of medicines in the 'ocular VEGF antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ocular VEGF antagonists' category:

• Cimerli (ranibizumab ophthalmic)
• faricimab ophthalmic

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.